Biophytis S.A. Signs Co-Development Agreement
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: co-development, partnership, filing
TL;DR
Biophytis S.A. inked a co-development deal on Jan 21, 2025.
AI Summary
On January 21, 2025, Biophytis S.A. announced the signing of a co-development agreement. The company is a foreign private issuer filing a Form 6-K report with the SEC, with its principal executive office located in Paris, France.
Why It Matters
This filing indicates Biophytis S.A. is actively pursuing strategic partnerships to advance its drug development pipeline.
Risk Assessment
Risk Level: low — This is a routine filing announcing a co-development agreement, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Stanislas Veillet (person) — Contact Person
- January 21, 2025 (date) — Date of Press Release
- March 20, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report the signing of a co-development agreement by Biophytis S.A., as announced in a press release on January 21, 2025.
Where is Biophytis S.A. headquartered?
Biophytis S.A.'s principal executive office is located at Sorbonne University—BC 9, Bâtiment A 4ème étage, 4 place Jussieu, 75005 Paris, France.
Who is listed as a contact person for Biophytis S.A. in this filing?
Stanislas Veillet is listed as a contact person for Biophytis S.A.
What is the SEC file number for Biophytis S.A.?
The SEC file number for Biophytis S.A. is 001-38974.
Does Biophytis S.A. file annual reports under Form 20-F or 40-F?
Biophytis S.A. indicates it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 by Stanislas Veillet regarding Biophytis SA.